Physician profile
Peter G Forstall
NPI 1982844098
$6,483.87
in general payments reported to CMS, 2019-2025
32 companies · $1,069 in 2025
The $1,069 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,427 · 2020: $278 · 2021: $364 · 2022: $410 · 2023: $1,208 · 2024: $1,728 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,005.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,912.09 | 2019-2025 | Watchman Flx, Farapulse, Watchman Access System |
| Medtronic, INC. | $1,221.71 | 2021-2025 | Azure Xt Dr Mri Surescan, Aurora Ev-Icd Mri Surescan, Micra |
| Medtronic Vascular, INC. | $785.85 | 2019-2020 | |
| Abbott Laboratories | $373.74 | 2019-2025 | Ensite Precision, Jot Dx, Aveir |
| Pfizer INC. | $372.76 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $272.89 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $240.58 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $141.84 | 2019-2024 | Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $123.72 | 2019-2024 | Lifevest |
| Amgen INC. | $100.49 | 2019-2023 | Repatha |
| Cvrx, INC. | $99.50 | 2021-2025 | Barostim Neo System |
| Biotronik INC. | $84.36 | 2024 | Biomonitor, Rivacor 7 Dr-T |
| Cardiva Medical, INC. | $73.46 | 2022-2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.52 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $70.54 | 2019-2025 | Farxiga |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $70.29 | 2023-2025 | Opsumit |
| Sanofi-Aventis U.S. LLC | $69.24 | 2019 | |
| Scpharmaceuticals INC. | $58.63 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $43.03 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $37.16 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $33.72 | 2019 | |
| Esperion Therapeutics, INC. | $31.07 | 2024 | Nexletol |
| Edwards Lifesciences Corporation | $26.30 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Philips North America LLC | $25.84 | 2024 | (5044) Mcot |
| Atricure, INC. | $22.05 | 2021 | |
| Astellas Pharma US INC | $21.13 | 2019 | |
| Lantheus Medical Imaging, INC. | $20.40 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.29 | 2025 | |
| Gilead Sciences, INC. | $17.34 | 2019 | |
| Inspire Medical Systems, INC. | $16.46 | 2023 | Inspire |
| Tactile Systems Technology INC | $13.75 | 2025 | Flexitouch Plus, Nimbl |
| Kowa Pharmaceuticals America, INC. | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Forstall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.